CN1367697A - 改善认识的疗法 - Google Patents

改善认识的疗法 Download PDF

Info

Publication number
CN1367697A
CN1367697A CN99812184A CN99812184A CN1367697A CN 1367697 A CN1367697 A CN 1367697A CN 99812184 A CN99812184 A CN 99812184A CN 99812184 A CN99812184 A CN 99812184A CN 1367697 A CN1367697 A CN 1367697A
Authority
CN
China
Prior art keywords
atypical antipsychotic
acetylcholinesterase inhibitor
patients
alzheimer
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99812184A
Other languages
English (en)
Chinese (zh)
Inventor
P·L·I·德尼斯
W·L·J·帕里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN1367697A publication Critical patent/CN1367697A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CN99812184A 1998-10-16 1999-10-12 改善认识的疗法 Pending CN1367697A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203454.8 1998-10-16
EP98203454 1998-10-16

Publications (1)

Publication Number Publication Date
CN1367697A true CN1367697A (zh) 2002-09-04

Family

ID=8234219

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99812184A Pending CN1367697A (zh) 1998-10-16 1999-10-12 改善认识的疗法

Country Status (20)

Country Link
EP (1) EP1121131A2 (id)
JP (1) JP2002527469A (id)
KR (1) KR20010072878A (id)
CN (1) CN1367697A (id)
AU (1) AU6472799A (id)
BG (1) BG105302A (id)
BR (1) BR9914419A (id)
CA (1) CA2345767A1 (id)
EE (1) EE200100136A (id)
HK (1) HK1039745A1 (id)
HR (1) HRP20010262A2 (id)
HU (1) HUP0103781A3 (id)
ID (1) ID28441A (id)
IL (1) IL142588A0 (id)
NO (1) NO20011403L (id)
PL (1) PL348107A1 (id)
SK (1) SK4592001A3 (id)
TR (1) TR200101082T2 (id)
WO (1) WO2000023057A2 (id)
ZA (1) ZA200103081B (id)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102841D0 (en) * 2001-02-05 2001-03-21 Novartis Ag Organic compounds
AU2006201188B2 (en) * 2001-02-05 2007-11-15 Novartis Ag New use of iloperidone
BRPI0213564B8 (pt) 2001-10-30 2021-05-25 Novartis Ag formulação depósito e micropartícula compreendendo iloperidona e polímero poli(d,l-lactídeo-co-glicolídeo), e processo para preparação da referida micropartícula
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
WO2006065233A1 (en) * 2004-12-10 2006-06-22 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
WO2005065645A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
MX2007008642A (es) * 2007-07-16 2009-02-25 World Trade Imp Export Wtie Ag Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente inhibidor reversible de la enzima colinesterasa, indicada para el control y tratamiento de trastornos psicoticos y demencias.
AU2011215870B2 (en) 2010-02-09 2016-01-28 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
WO1992020327A1 (en) * 1991-05-14 1992-11-26 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
JP4640888B2 (ja) * 1997-08-11 2011-03-02 ザ ユニヴァーシティー オブ サウス フロリダ 神経精神性疾患用ニコチンアンタゴニスト
EP1073432B1 (en) * 1998-04-14 2007-08-15 The General Hospital Corporation Use of d-serine or d-alanine for treating schizophrenia

Also Published As

Publication number Publication date
WO2000023057A3 (en) 2000-07-27
TR200101082T2 (tr) 2001-09-21
HRP20010262A2 (en) 2002-06-30
HUP0103781A2 (hu) 2002-03-28
HK1039745A1 (zh) 2002-05-10
NO20011403D0 (no) 2001-03-20
WO2000023057A2 (en) 2000-04-27
HUP0103781A3 (en) 2003-09-29
AU6472799A (en) 2000-05-08
CA2345767A1 (en) 2000-04-27
BR9914419A (pt) 2001-06-26
NO20011403L (no) 2001-03-20
EP1121131A2 (en) 2001-08-08
SK4592001A3 (en) 2001-12-03
BG105302A (en) 2001-11-30
KR20010072878A (ko) 2001-07-31
IL142588A0 (en) 2002-03-10
PL348107A1 (en) 2002-05-06
ID28441A (id) 2001-05-24
ZA200103081B (en) 2002-07-12
JP2002527469A (ja) 2002-08-27
EE200100136A (et) 2002-06-17

Similar Documents

Publication Publication Date Title
CN1367697A (zh) 改善认识的疗法
US9782403B2 (en) Treating sexual desire disorders with flibanserin
US6444665B1 (en) Method for treating pain
EP2727590B1 (en) Compositions for treating centrally mediated nausea and vomiting
MX2013001345A (es) Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil-)-4-fenil-4'.9'-dihidro-3'h-espi ro[ciclohexan-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento de dolor neuropatico.
CA2608713A1 (en) Method for the treatment of sexual dysfunctions due to medical conditions
CN117412747A (zh) 用于治疗激越的方法和组合物
JP2003521462A (ja) 男性における器質性勃起機能不全治療のための医薬品製造におけるアポモルヒネの使用
WO2011120281A1 (zh) 左旋奥拉西坦在制备预防或治疗认知功能障碍药物中的应用
AU2020377451B2 (en) Oral formulation of X842
CN1317030C (zh) 用中等剂量的lhrh拮抗剂治疗阿尔茨海默氏病
JP2004505036A5 (id)
KR100708560B1 (ko) 미르타자핀을 포함한 경구 붕해성 조성물
JP2012500248A (ja) 不安障害の治療
JP2025510311A5 (id)
WO2020014072A1 (en) Neostigmine pharmaceutical combination for treating myasthenia gravis
EP0671908B1 (en) Pharmaceutical compositions comprising 5-ht 1? receptor agonists and absorption enhancers
US20090124606A1 (en) Composition for Treatment of Psychosis
WO2002056869A2 (en) Method for treating sexual disorders
NZ788973B2 (en) Treating behavioral and psychological symptoms in dementia patients
Binns et al. A review of the law on second medical use patent claims: Have the English Courts gone too far in restricting second medical use claims?
RU2023123363A (ru) Деструкторы irak4 и их применение
WO2005058878A1 (ja) 月経困難症の予防および／または治療剤
WO2004026312A1 (en) Use of a quinazoline derivative for treating lower urinary tract symptoms
WO1995027486A1 (en) Low dosage ranitidine compositions for the treatment of minor gastrointestinal disorders associated with excess acid secretion

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication